Paul Lytle

Mr. Lytle brings over 30 years of finance and accounting experience, over 25 years of public company experience for Nasdaq listed companies, and over 25 years of biotechnology experience primarily focused on the development and manufacturing of immunotherapies for the treatment of cancer. Mr. Lytle’s biotechnology career started with Avid Bioservices, Inc. (Nasdaq: CDMO) (f/k/a Peregrine Pharmaceuticals, Inc.) from 1997 to 2018, where he raised in excess of $500 million in net proceeds from various equity and debt offerings, including an initial public offering of convertible notes, while serving as Chief Financial Officer for over 18 years. Mr. Lytle was also instrumental in the formation of a successful biologics manufacturing business utilizing excess manufacturing capacity at Avid. Mr. Lytle is a co-founder of Thendor Therapeutics, LLC, a private biopharmaceutical company, and he has served as its Chief Financial Officer since September 2023. Mr. Lytle is also the co-founder of Mosaic ImmunoEngineering, Inc., a public development-stage biotechnology company, and he has served on its board of directors and as its Executive Vice President, Chief Financial Officer since August 2020. Previously, Mr. Lytle served as Executive Vice President, Chief Financial Officer of Breathe Technologies, Inc., a private medical device company, from September 2018 to December 2019 where he and the team successfully navigated the acquisition by Hillrom Holdings (2019). Mr. Lytle started his career at Deloitte in 1992.

Mr. Lytle received his B.S. in Business with an emphasis in Accounting from California State University at Long Beach and is a Certified Public Accountant (inactive).